Combined modality therapy of resectable rectal cancer: Current approaches

Techniques in Coloproctology

Volumn 8, Issue 2, 2004, Pages 67-76

  Minsky, B D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adjuvant therapy; Chemoradiation; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; RALTITREXED; UFT;

ANUS SPHINCTER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; HUMAN; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGNOSIS; RECTUM CANCER; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 4344560430     PISSN: 11236337     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10151-004-0059-3     Document Type: Review

References (117)

1. - (1990) NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450
2. Skibber JM, Hoff PM, Minsky BD (2001) Cancer of the rectum. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott, Williams Wilkins, Philadelphia, pp 1271-1318
3. Bosset JF, Horiot JC, Hamers HP et al (2001) Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol 61:7-13
4. Lee JHL, Lee JH, Ahn JH et al (2002) Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol 20:1751-1758
5. Krook JE, Moertel CG, Gunderson LL et al (1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715
6. Smalley SR, Benedetti J, Williamson S et al (2003) Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs. prolonged venous infusion (PVI) before and after XRT + PVI vs. bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc Am Soc Clin Oncol 22:251 (abstract 1006)
7. Tepper JE, O'Connell MJ, Niedzwiecki D et al (2002) Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control. Final report of Intergroup 0114. J Clin Oncol 20:1744-1750
8. Minsky BD, Cohen AM, Enker WE et al (1992) Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol 10:1218-1224
9. Minsky BD (1998) Preoperative radiation therapy followed by low anterior resection with coloanal anastomosis. Semin Radiat Oncol 8:30-35
10. Sauer R (2003) Adjuvant versus neoadjuvant combined modality therapy for locally advanced rectal cancer: first results of the German Rectal Cancer Study (CAO/ARO/AIO-94). Int J Radiat Oncol Biol Phys 57:S124
11. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC (1999) Prognostic factors in stage T3N0 rectal cancer: do all patients require post-operative pelvic irradiation and chemotherapy? Dis Colon Rectum 42:167-173
12. Merchant NB, Guillem JG, Paty PB et al (1999) T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 3:642-647
13. American Joint Committee on Cancer (2002) Colon and rectum. In: Green FL, Page DL, Fleming ID et al (eds) AJCC cancer staging manual, 6th edn. Springer, Berlin Heidelberg New York, pp 113-124
14. Gunderson LL, Sargent D, Tepper J et al (2003) Impact of TN stage and treatment on survival and relapse in adjuvant rectal cancer pooled analysis. Proc Am Soc Clin Oncol 22:251 (abstract 1008)
15. Green FL, Stewart AK, Norton HJ (2003) A new TNM staging strategy for node-positive (stage III) rectal cancer: an analysis of 5998 patients. Proc Am Soc Clin Oncol 22:251
16. Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. JAMA 284:1008-1015
17. Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 358:1291-1304
18. Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980-987
19. Kapiteijn E, Marijnen CAM, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646
20. van de Velde CJH (2002) Preoperative radiotherapy and TME-surgery for rectal cancer: detailed analysis in relation to quality control in a randomized trial. Proc Am Soc Clin Oncol 21:127 (abstract 506)
21. Marijnen CAM, Kapiteijn E, van de Velde CJH et al (2002) Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 20:817-825
22. Marijnen CAM, Nagtegaal ID, Kapiteijn E et al (2003) Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55:1311-1320
23. Beets-Tan RGH, Beets GL (2003) Rectal cancer: how accurate can imaging predict the T stage and the circumferential resection margin? Int J Colorec Dis 18:385-391
24. Graf W, Dahlberg M, Osman MM et al (1997) Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiother Oncol 43:133-137
25. Marijnen CAM, Nagtegaal ID, Kranenbarg EK et al (2001) No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19:1976-1984
26. Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17:2396-2402
27. Rouanet P, Saint Aubert B, Lemanski C et al (2002) Restorative and nonrestorative surgery for low rectal cancer after high dose radiation. Long term oncologic and functional results. Dis Colon Rectum 45:305-315
28. Wagman R, Minsky BD, Cohen AM et al (1998) Sphincter preservation with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 42:51-57
29. Hyams DM, Mamounas EP, Petrelli N et al (1997) A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum. A progress report of the National Surgical Adjuvant Breast and Bowel Project protocol R0-3. Dis Colon Rectum 40:131-139
30. Valentini V, Coco C, Cellini N et al (1998) Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 40:1067-1075
31. Grann A, Feng C, Wong D et al (2001) Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 49:987-995
32. Kuvshinoff B, Maghfoor I, Miedema B et al (2001) Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are <1 cm distal margins sufficient? Ann Surg Oncol 8:163-169
33. Mehta VK, Cho C, Ford JM et al (2003) Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132-137
34. Grann A, Feng C, Wong D et al (2000) Pre-oP combined modality therapy (CMT) for uT3 rectal cancer. Proc Am Soc Clin Oncol 19:249 (abstract 967)
35. Moore HG, Riedel E, Minsky BD et al (2003) Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined modality therapy. Ann Surg Oncol 10:80-85
36. Grumann MM, Noack EM, Hoffman IA et al (2001) Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. Ann Surg 233:149-156
37. Kollmorgen CF, Meagher AP, Pemberton JH et al (1994) The long term effect of adjuvant postoperative chemoradiotherapy for rectal cancer on bowel function. Ann Surg 220:676-682
38. Valero G, Lujan JA, Hernandez Q et al (2003) Neoadjuvant radiation and chemotherapy in rectal cancer does not increase postoperative complications. Int J Colorectal Dis 18:495-499
39. Påhlman L, Glimelius B (1990) Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 211:187-195
40. Roh MS, Petrelli N, Weiand H et al (2001) Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). Proc Am Soc Clin Oncol 20:123 (abstract)
41. Beets-Tan RGH, Beets GL, Vliegen RFA et al (2001) Accuracy of magnetic resonance imaging in prediction of tumor-free resection margin in rectal cancer surgery. Lancet 357:497-504
42. Onaitis MW, Noone RB, Fields R et al (2001) Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 8:801-806
43. Stein DE, Mahmoud NN, Anne PR et al (2003) Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 46:448-453
44. Janjan NA, Crane C, Feig BW et al (2001) Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24:107-112
45. Read TE, Ogunbiyi OA, Fleshman JW et al (2001) Neoadjuvant external beam radiation and proctectomy for adenocarcinoma of the rectum. Dis Colon Rectum 44:1778-1790
46. Hiotis SP, Weber SM, Cohen AM et al (2002) Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 194:131-136
47. Ruo L, Tickoo S, Klimstra DS et al (2002) Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236:75-81
48. Valentini V, Coco C, Picciocchi A et al (2002) Does down-staging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53:664-674
49. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P et al (2003) A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 46:298-304
50. Mohiuddin M, Hayne M, Regine WF et al (2000) Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 48:1075-1080
51. Luna-Perez P, Segura J, Alvarado I et al (2000) Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 7:727-731
52. Villafranca E, Okruzhnov Y, Dominguez MA et al (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779-1786
53. Esposito G, Pucciarelli S, Alaggio R et al (2001) p27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 8:311-318
54. Elsaleh H, Robbins P, Joseph D et al (2000) Can p53 alterations be used to predict tumor response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol 56:239-244
55. Kandioler D, Zwrtek R, Ludwig C et al (2002) TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 235:493-498
56. Schwander O, Bruch HP, Broll R (2002) p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance? Int J Colorectal Dis 17:11-19
57. Saw RPM, Morgan M, Koorey D et al (2003) p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 46:192-202
58. Adell GCE, Zhang H, Evertsson S et al (2001) Apoptosis in rectal cancer. Prognosis and recurrence after preoperative radiotherapy. Cancer 91:1870-1875
59. Rodel C, Grabenbauer GG, Papadopoulos T et al (2002) Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 52:294-303
60. Scott N, Hale A, Deakin M et al (1998) A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53, and bcl-2 expression. Eur J Surg Oncol 24:169-173
61. Giralt J, Eraso A, Armengol M et al (2002) Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 54:1460-1465
62. Adell G, Zhang H, Jansson A et al (2001) Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 50:659-663
63. Habr-Gama A, Santinho B.de Souza PM, Ribeiro U et al (1998) Low rectal cancer. Impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 41:1087-1096
64. Barbaro B, Schulsinger A, Valentini V et al (1999) The accuracy of transrectal ultrasound in predicting the pathological stage of low-lying rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 43:1043-1047
65. Gavioli M, Bagni A, Piccagli I et al (2000) Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer. Dis Colon Rectum 43:1075-1083
66. Guillem JG, Puig-La Calle J, Akhurst T et al (2000). Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 43:18-24
67. Guillem JG, Moore HG, Akhurst T et al (2002) Prospective evaluation of the prognostic significance of FDG-PET assessment of rectal cancer response to preoperative chemoradiation. Proc Am Soc Clin Oncol 21:145 (abstract)
68. Dzik-Jurask A, Domenig C, George M et al (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307-308
69. Cox JD, Guse C, Asbell S et al (1998) Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: results of protocol 83-08 of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 15:1331-1336
70. Coucke PA, Cuttat JF, Mirimanoff RO (1993) Adjuvant postoperative accelerated hyperfractionated radiotherapy in rectal cancer: a feasibility study. Int J Radiat Oncol Biol Phys 27:885-889
71. Coucke PA, Sartorelli B, Cuttat JF et al (1995) The rationale to switch from postoperative hyperfractionated accelerated radiotherapy to preoperative hyperfractionated accelerated radiotherapy in rectal cancer. Int J Radiat Oncol Biol Phys 32:181-188
72. Stupp R, Matter M, Volter V et al (2001) Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal cancer (LARC): a phase I study. Int J Radiat Oncol Biol Phys 51:11
73. Janjan NA, Crane C, Feig BW et al (2000) Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 47:713-718
74. Movsas B, Hanlon A, Lanciano R et al (1998) Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 42:43-50
75. Diratzouian H, Movsas B, Hanlon AL et al (2001) Phase II trial of preoperative chemoradiation with a hyperfractionated RT boost in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 51:10
76. Myerson RJ, Valentini V, Birnbaum EH et al (2001) A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys 50:1299-1308
77. Tait DM, Nahum AE, Meyer LC et al (1997) Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother Oncol 42:121-136
78. Shank B, LoSasso T, Brewster L et al (1991) Three-dimensional treatment planning for post-operative treatment of rectal carcinoma. Int J Radiat Oncol Biol Phys 21:253-265
79. Tatsuzaki H, Urie MM, Willett CG (1991) 3-D comparative study of proton vs. x-ray radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 22:369-374
80. Duncan W, Arnott SJ, Jack WJL et al (1987) Results of two randomized trials of neutron therapy in rectal adenocarcinoma. Radiother Oncol 8:191-198
81. Anscher MS, Lee C, Hurwitz HI et al (2000) A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. Int J Radiat Oncol Biol Phys 47:719-724
82. Rau B, Wust P, Tilly W et al (2000) Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters. Int J Radiat Oncol Biol Phys 48:381-391
83. van der Zee J, Gonzalez DG, van Rhoon GC et al (2000) Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumors: a prospective, randomised, multicenter trial. Lancet 355:1119-1125
84. Juffermans JHM, Hanssens PEJ, Van Putten WLJ et al (2003) Reirradiation and hyperthermia in rectal carcinoma. A retrospective study on palliative effect. Cancer 98:1759-1766
85. Rothenberg MA, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059-2069
86. Rothenberg MA, Oza A, Burger B et al (2003) Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan. Proc Am Soc Clin Oncol 22:252 (abstract)
87. Goldberg RM, Morton RF, Sargent DJ et al (2003) N9741: Oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life. Proc Am Soc Clin Oncol 22:252 (abstract)
88. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914
89. Uzcudun AE, Batlle JF, Velasco JC et al (2002) Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin. Dis Colon Rectum 45:1349-1353
90. Carraro S, Roca EL, Cartelli C et al (2002) Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys 54:397-402
91. Fernandez-Martos C, Aparicio J, Bosch C et al (2003) Combined modality treatment with oxaliplatin, oral uracil and tegafur (UFT) and concomitant irradiation (RT) in rectal cancer. A dose finding study. Proc Am Soc Clin Oncol 22:322 (abstract)
92. James RD, Botwood N, Vernon CC et al (2003) Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study. Ann Oncol 14:570-573
93. Valentini V, Morganti AG, Gambacorta MA et al (2002) Raltitrexed (Tomudex) and oxaliplatin (Tomox) preliminary results of a phase II study of chemoradiation with preoperative treatment of stage II/III resectable rectal cancer. Proc Am Soc Clin Oncol 21:151 (abstract)
94. Sebag-Montefiore D, Glynne-Jones R, Falk S et al (2002) Preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer. Proc Am Soc Clin Oncol 21:146 (abstract)
95. Gerard JP, Chapet O, Nemoz C et al (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 21:1119-1124
96. Landry JC, Rosenthal D, Spitz FR et al (2003) ECOG 1297: a phase I study of preoperative radiation therapy (RT) with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 57:S179
97. Rodel C, Grabenbauer GG, Papadopoulos T et al (2003) Phase I/II trial of capecitibine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098-2104
98. Aschele C, Friso ML, Pucciarelli S et al (2002) A phase I-II study of weekly oxaliplatin (OXA) 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 21:132 (abstract)
99. Ngan S, Rischin D, Michael M et al (2003) A phase I trial of radiotherapy, oxaliplatin and infusional 5-fluorouracil (5FU) for patients with rectal cancer not suitable for curative resection. Proc Am Soc Clin Oncol 22:291 (abstract)
100. Glynne-Jones R, Sebag-Montefiore D, McDonald A et al (2003) A phase I study of preoperative radiation and capecitabine in combination with oxaliplatin in locally advanced rectal cancer. Proc Am Soc Clin Oncol 22:292 (abstract)
101. Eric F, Marc Y, Michel D et al (2003) A phase I study of 5-fluorouracil continuous infusion (5FU CI), weekly oxaliplatin (OXA) and radiotherapy (RT) in advanced rectal cancer. Proc Am Soc Clin Oncol 22:344 (abstract)
102. Freyer G, Bossard N, Romestaing P et al (2001) Addition of oxaliplatin to continuous infusion fluorouracil, 1-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 19:2433-2438
103. Rosenthal DI, Catalano P, Haller DG et al (2003) ECOG 1297: a phase I study of preoperative radiation therapy (RT) with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal adenocarcinoma. Proc Am Soc Clin Oncol 22:273 (abstract)
104. Voelter V, Stupp R, Matter M et al (2003) Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study. Int J Radiat Oncol Biol Phys 56:1288-1294
105. Levine EL, Gollins S, Susnerwala S et al (2003) Phase I/II study of irinotecan (CPT-11), 5-fluorouracil and concurrent radiotherapy for the treatment of T3-T4 locally advanced inoperable rectal cancer. Proc Am Soc Clin Oncol 22:345 (abstract)
106. Navarro M, Dotor E, Rivera F et al (2003) A phase II study of irinotecan (CPT-11) and 5-fluorouracil (5-FU) concomitantly with preoperative radiotherapy (RT) in patients with locally advanced resectable rectal cancer. Proc Am Soc Clin Oncol 22:308 (abstract)
107. Mitchell EP, Anne PR, Fry RD et al (2003) Chemoradiation with CPT-11, 5FU, in neoadjuvant treatment of locally advanced or recurrent adenocarcinoma of the rectum: a phase I/II study update. Proc Am Soc Clin Oncol 22:262 (abstract)
108. Minsky BD (2002) Combined modality therapy for rectal cancer using irinotecan. Oncology 16s:35-38
109. Ranson M, Hammond LA, Ferry D et al (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20:1512-1521
110. Souglakos J, Androulakis N, Mavroudis D et al (2003) Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys 56:1284-1287
111. Dunst J, Reese T, Sutter T et al (2002) Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:3983-3991
112. Dunst J, Reese T, Hoelscher T et al (2003) Capecitabine combined with radiotherapy as neoadjuvant treatment of locally advanced rectal cancer. Proc Am Soc Clin Oncol 22:277 (abstract)
113. Cunningham D, Humblet Y, Siena S et al (2003) Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 22:252 (abstract)
114. Chau I, Cunningham D, Tait D et al (2003) Twelve weeks of neoadjuvant capecitabine (cap) and oxaliplatin (ox) followed by synchronous chemoradiation (CRT) and total mesorectal excision (TME) in MRI defined poor risk locally advanced rectal cancer resulted in promising tumor regression and rapid symptomatic relief. Proc Am Soc Clin Oncol 22:271 (abstract)
115. Calvo FA, Serrano F, Gomez-Espi M et al (2003) Induction oxaliplatin + 5-FU improves further the incidence of pT0 down-staged surgical specimens in >cT3 rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 57:S178
116. Klautke G, Kirchner R, Hopt U et al (2001) Continuous infusion of 5-FU and weekly irinotecan with concurrent radiotherapy as neoadjuvant treatment for locally advanced or recurrent rectal cancer. Proc Am Soc Clin Oncol 20:140 (abstract)
117. Mitchell EP, Anne P, Fry R et al (2001) Combined modality therapy of locally advanced or recurrent adenocarcinoma of the rectum: report of a phase I trial of chemotherapy (CT) with CPT-11, 5-FU and concomitant irradiation (RT). Proc Am Soc Clin Oncol 20:131 (abstract)